ConCallIQ
Go Pro
AGARWALEYE Diversified 10 Feb 2026

Dr. Agarwal's Health Care Limited — Q3 FY26

Dr.

bullish high
Compare with...
Revenue ₹530 Cr +23%
EBITDA ₹155 Cr +21.3%
PAT ₹44 Cr +55%
EBITDA Margin 28.4%
Duration 52 min
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Slower ramp-up in new geographies

New facilities in non-core markets like Delhi and Ethiopia may take 15-18 months to break even, potentially pressuring near-term margins.

medium · management_commentary
R

Refractive surgery slowdown

Refractive surgery volumes were slower this year due to industry-wide softness, which could persist and impact growth.

medium · analyst_question
R

Revenue per facility decline in newer regions

Analyst noted a drop in revenue per facility in the east region; management attributed it to early-stage facilities, but sustained underperformance could signal competitive pressure.

low · data_observation
R

Labor code implementation risk

New labor codes could increase employee costs; management assessed impact as not material currently but continues to monitor.

low · management_commentary